Project Grant R01CA290014
Award Date
5/1/24
Completion Date
4/30/29
Dollars Obligated
$1.9M
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is focused on developing nano-scale contrast agents that enable continuous and high-fidelity ultrasound (US) imaging of immune cells in deep tissues. The goal is to use these phase-changing peptide nanoemulsions (NPEPs) to monitor the migration and persistence of tumoricidal chimeric antigen receptor macrophages (CAR-M) in vivo, as an exemplary cellular...
This Project Grant award, valued at $496,567 and awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) on June 1, 2024, will support research to develop, validate, and implement advanced computational tumor phenotyping techniques to characterize head and neck squamous cell carcinoma (HNSCC) at multiple biological levels. The research involves high-throughput analysis of quantitative features from radiology images (radiomics) and digital pathology images...
The National Cancer Institute (NCI) awarded a 5-year, $643,522 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of Southern California to develop a new multiplexed molecular imaging strategy using Raman-active nanoparticles. This innovative technology aims to provide high-content molecular profiling and high-resolution spatial analysis of patient tissue samples in a single histology image. The project will focus initially on interrogating the tumor immune...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $676,006 to The Regents of the University of California, San Francisco (UCSF) to develop and test strategies for early identification of resistance to immunotherapy for cancer. The key products and services to be delivered include: Utilizing PET imaging to measure biomarkers of response (granzyme B) and resistance (neutrophil levels) early after immunotherapy...
This $399,829 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research at The Washington University in St. Louis to develop PET imaging approaches for predicting and monitoring gastric cancer patient response to HER2-targeting antibody-drug conjugate (ADC) therapies. The key objectives are to: Use PET imaging techniques to quantify tumor expression of the S1PR1 receptor, which preclinical data suggests is associated with...
The National Cancer Institute (NCI) awarded a $619,294 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of California, San Diego (UCSD) to develop and test slow-release CPMV-polymer blend formulations for intratumoral immunotherapy delivery. The project aims to address key challenges with intratumoral immunotherapy, including large tumor volumes, high fluid pressure, and frequent dosing requirements, by developing injectable CPMV-polymer implants and...
The National Cancer Institute (NCI) awarded a $218,089 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of California, Santa Barbara (UCSB) to develop and evaluate a novel Chimeric Antigen Receptor Macrophage (CAR-M) immunotherapy for the treatment of triple-negative breast cancer (TNBC). The key products or services to be delivered under this 2-year award include: 1) Evaluating the specificity, efficacy, and impact on angiogenesis of an anti-CSPG4...
The National Cancer Institute (NCI) awarded a $599,191 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of California, San Diego (UCSD) to develop and validate a new computational framework for characterizing complex tumor vascular properties using 3D dynamic contrast-enhanced ultrasound (3D DCE-US) imaging. The 5-year project aims to capture novel information about tumor vasculature beyond conventional perfusion parameters, with the goal of improving...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support a Phase I clinical trial to evaluate the safety and efficacy of CSPG4-targeted CAR-T cell therapy in adult patients with head and neck squamous cell carcinoma (HNSCC) that is refractory to platinum chemotherapy and PD-1 inhibition. The $627,456 award to the University of North Carolina at Chapel Hill will fund the conduct of the single-center, open-label study using a modified 3+3...
This $235,417 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports the identification and evaluation of splice variant-derived neoantigens as potential targets for tumor vaccine development against head and neck squamous cell carcinoma (HNSCC). The research aims to leverage computational methods to predict and prioritize splice variant-derived peptides, assess their immunogenicity in a murine oral cancer model, and then incorporate promising...